Recent trends suggest there may be little growth globally in the number of anti-infective vaccines entering clinical trials for the rest of this decade, according to a recent analysis from the Tufts Center for the Study of Drug Development. “Despite widespread agreement that new vaccines are an important public health priority, development remains slow, expensive, and risky,” said Tufts CSDD Director Kenneth I. Kaitin. According to the study, since 199...